Effect of QRS Duration and Morphology on Cardiac Resynchronization Therapy Outcomes in Mild Heart Failure

Results From the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) Study

Michael R. Gold, MD, PhD; Christophe Thébault, MD; Cecilia Linde, MD, PhD; William T. Abraham, MD; Bart Gerritse, PhD; Stefano Ghio, MD; Martin St. John Sutton, MD, FRCP; Jean-Claude Daubert, MD

Background—Cardiac resynchronization therapy (CRT) decreases mortality, improves functional status, and induces reverse left ventricular remodeling in selected populations with heart failure. We aimed to assess the impact of baseline QRS duration and morphology and the change in QRS duration with pacing on CRT outcomes in mild heart failure.

Methods and Results—Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) was a multicenter randomized trial of CRT among 610 patients with mild heart failure. Baseline and CRT-paced QRS durations and baseline QRS morphology were evaluated by blinded core laboratories. The mean baseline QRS duration was 151±23 milliseconds, and 60.5% of subjects had left bundle-branch block (LBBB). Patients with LBBB experienced a 25.3-mL/m² mean reduction in left ventricular end-systolic volume index (P<0.0001), whereas non-LBBB patients had smaller decreases (6.7 mL/m²; P=0.18). Baseline QRS duration was also a strong predictor of change in left ventricular end-systolic volume index with monotonic increases as QRS duration prolonged. Similarly, the clinical composite score improved with CRT for LBBB subjects (odds ratio, 0.530; P=0.0034) but not for non-LBBB subjects (odds ratio, 0.724; P=0.21). The association between clinical composite score and QRS duration was highly significant (odds ratio, 0.831 for each 10-millisecond increase in QRS duration; P<0.0001), with improved response at longer QRS durations. The change in QRS duration with CRT pacing was not an independent predictor of any outcomes after correction for baseline variables.

Conclusion—REVERSE demonstrated that LBBB and QRS prolongation are markers of reverse remodeling and clinical benefit with CRT in mild heart failure.

Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00271154.

(Circulation. 2012;126:822-829.)

Key Words: bundle-branch block ■ pacing ■ cardiomyopathy ■ heart failure

Cardiac resynchronization therapy (CRT) improves functional status and cardiac function and decreases heart failure (HF) hospitalizations and mortality among HF patients with left ventricular (LV) systolic dysfunction and QRS prolongation.1–8 Initially, CRT was applied to patients with advanced HF, but more recent studies have shown similar benefit among patients with milder HF.9–11 Several studies have demonstrated that the hemodynamic response, extent of LV volumetric changes (ie, reverse remodeling), and clinical outcomes are affected by baseline or CRT-paced ECG characteristics.6,12–16 These studies suggest that patients with longer intrinsic QRS duration, left bundle-branch block (LBBB) morphology, and greater QRS shortening with biventricular pacing have better outcomes. Conversely, those with non-LBBB morphology do not benefit from or may even worsen with CRT. However, a comprehensive evaluation of QRS duration and morphology on structural and clinical outcomes with CRT has not been performed previously. Accordingly, the present analysis was designed to evaluate the role of intrinsic and CRT-paced QRS characteristics on CRT in the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study.

© 2012 American Heart Association, Inc.
Methods

The design and primary results of the REVERSE trial were published previously. Briefly, eligible patients had American College of Cardiology/American Heart Association stage C or New York Heart Association class I (previously symptomatic, currently asymptomatic) or class II (mildly symptomatic) HF for at least 3 months before enrollment. Patients were required to be in sinus rhythm with a QRS duration $\geq 120$ milliseconds, an ejection fraction $\leq 40\%$, and an LV end-diastolic dimension $\geq 55$ mm measured by transthoracic echocardiography. All patients were receiving optimal medical therapy for HF, including stable doses of an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker or class I (previously symptomatic, currently asymptomatic) or class II (mildly symptomatic) HF for at least 3 months before enrollment. Patients were required to be in sinus rhythm with a QRS duration $\geq 120$ milliseconds, an ejection fraction $\leq 40\%$, and an LV end-diastolic dimension $\geq 55$ mm measured by transthoracic echocardiography. All patients were receiving optimal medical therapy for HF, including stable doses of an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker or a $\beta$-blocker. Patients requiring pacing were excluded. The ethics committee of each center approved the study protocol, and all patients gave written informed consent.

All patients underwent implantation of a CRT system (device and leads), with or without implantable cardioverter-defibrillator capabilities, on the basis of standard clinical criteria. Patients who had undergone successful implantation ($n=610$) were then randomly assigned in a 2:1 fashion to active CRT (CRT ON) or to a control group (CRT OFF). By study design, patients were followed up in their randomized arms for 12 months in North America and for 24 months in Europe. Those assigned to CRT ON were programmed to simultaneous biventricular pacing in the DDI mode at a lower rate of 35 bpm. Those patients randomized to CRT OFF were programmed to the DDI mode at a lower rate of 35 bpm.

Analyses were performed on 12-lead ECGs collected at baseline and after successful CRT implantation but before randomization to CRT ON or OFF by researchers at core laboratories who were blinded to randomization assignment and clinical outcomes. Consequently, patients had not received CRT before these measurements were made. Intrinsic QRS morphology and duration were measured, as well as CRT-paced QRS duration. Both intrinsic QRS duration and paced QRS duration were measured on a tracer table as the mean from 9 consecutive cycles in leads II, V$_6$, and V$_a$. The intraobserver and interobserver reproducibilities were evaluated by a second measurement of 50 randomly selected ECGs prepared by another expert interpreter. The intraobserver and interobserver coefficients of variability of the unpaced and paced QRS complexes were 1.6% and 1.4%, and 6.4% and 2.6%, respectively. Morphology was classified as LBBB, right bundle-branch block (RBBB), or nonspecific intraventricular conduction delay (IVCD) by World Health Organization criteria. LBBB was thus defined as QRS duration $\geq 120$ milliseconds; QS or rS in lead V$_1$; broad R waves in leads I, aVL, V$_6$, or V$_a$; and absent q waves in leads V$_2$ and V$_3$. For the purpose of the present analyses, all other patients were classified as a non-LBBB cohort. In addition, analyses were performed with the non-LBBB cohort subdivided into subgroups of RBBB, IVCD, and narrow QRS ($<120$ milliseconds). In the overall study, each center interpreted the ECG and baseline echocardiography independently of the core laboratories to determine criteria for study entry, including QRS duration. Of note, core laboratory evaluation of QRS data was performed after enrollment; thus, some patients were classified as narrow QRS even though study inclusion criteria specified a QRS duration $\geq 120$ milliseconds.

The primary end point of REVERSE was the clinical composite score (CCS). Using this end point, we classified patients into 1 of 3 response groups: worsened, unchanged, or improved. Patients were judged to be worsened if they died, were hospitalized for worsening HF, crossed over to or permanently discontinued double-blind treatment owing to worsening HF, or demonstrated worsening in New York Heart Association class or moderate to marked worsening of patient global assessment. Patients were judged to be improved if they had not worsened and had demonstrated improvement in New York Heart Association class and/or a moderate to marked improvement in patient global assessment. Patients who were not worsened or improved were classified as unchanged.

Echocardiograms were obtained at baseline and after 12 months of randomization. Data were analyzed in 1 of 2 core laboratories by researchers blinded to clinical data. LV dimensions were recorded with 2-dimensional directed M-mode echocardiography at the tips of the mitral valve leaflets. Echocardiograms were digitized to obtain LV volumes by the Simpson method of disks, as recommended by the American Society of Echocardiography, from which LV ejection fraction was calculated. Change in LV end-systolic volume indexed by body surface area (LVESVi) was the predefined and independently powered secondary end point of REVERSE. Further details of the echocardiographic protocol have been published previously.

Data Analysis

Continuous variables are summarized with mean and standard deviation; categorical variables, with counts and percentages. Comparisons of baseline variables between patients with and without LBBB use the Student $t$ test and Fisher exact test. Outcome parameters were analyzed with regression models that include some or all of QRS duration, LBBB, and study arm, with interactions. Effect estimates and $P$ values were derived from contrasts. Interaction $P$ values are reported to assess the difference of the effect of CRT between LBBB and non-LBBB. The CCS was analyzed as a 3-category ordinal variable by use of ordinal logistic regression. A reported odds ratio $<1$ indicates improvement; ie, patients are less likely to be in the worse categories. Echocardiographic parameters were analyzed with linear regression. Time-to-event analyses used Kaplan–Meier estimates and Cox proportional hazards regression to compute hazard ratios and to assess influence of covariates. Survival curves and rates were compared by the log-rank test. To assess possible confounding by baseline characteristics that differ between patients with and without LBBB, those characteristics with $P<0.10$ were added to the models to observe qualitative changes in the relation between outcome parameters and LBBB. The relation between QRS duration and outcomes is graphically illustrated with smooth curves fitted to the data using a cubic spline method. This technique extends the standard fitting of straight regression lines and finds a curve that optimally balances goodness of fit against minimal curvature.

The immediate QRS change is the difference between unpaced baseline QRS and biventricular paced QRS measured before permanent CRT programming. Normalized acute QRS change was calculated by subtracting the expected QRS change based on baseline QRS as calculated from a linear regression model. A value of $P<0.05$ was considered statistically significant.

Patient Population

All 610 patients randomized in REVERSE were included in this analysis. Demographic and other characteristics of the patient population are presented in Table 1. The mean age was $62.5\pm11.0$ years; 79% were male; and 55% had ischemic heart disease as the primary cause of HF. The mean ejection fraction was $26.7\pm7.0\%$. The intrinsic QRS duration could be determined by the core laboratory for 582 patients and was $151\pm23$ milliseconds. QRS morphology could be determined by the core laboratory for 593 patients. For 14 patients, the classification by the investigator was used in analysis. For the remaining 3 patients, QRS morphology remains unknown. Table 1 also shows the patient characteristics grouped by QRS morphology. There was no significant difference in the proportion of patients in the CRT ON versus OFF groups with LBBB (61.1% versus 59.2%, respectively). However, there are some important differences between the groups. Specifically, subjects with LBBB were less likely to be men,
to have diabetes mellitus, or to have an ischemic type of HF. The LBBB group also had significantly longer intrinsic QRS duration with a mean of 159 milliseconds compared with 139 milliseconds in the non-LBBB group (P<0.0001) and better functional status as evidenced by quality-of-life scores and 6-minute hall-walk distances. The non-LBBB group consisted of 57 patients with narrow QRS (<120 milliseconds), 55 patients with RBBB, and 126 patients with IVCD.

**Echocardiographic Changes**

One of the hallmark findings of CRT is the reduction of LV volumes and the increase in LV ejection fraction as part of the reverse remodeling response. Paired baseline and 12-month echocardiographic data were available for 509 patients, with an overall LVESVi reduction of 18.3±28.9 mL/m² in the CRT ON arm. The results for change in LVESVi at 12 months grouped by QRS morphology are shown in Table 2. There was a large reduction of LVESVi with CRT noted in this study that was observed primarily in the LBBB cohort. For the LBBB group, there was a 25.3-mL/m² mean reduction in LVESVi (P<0.0001 versus CRT OFF), whereas in the non-LBBB group, this decrease was much smaller and nonsignificant (6.7 mL/m²; P=0.18). LV end-diastolic volume index showed a similar relationship with QRS morphology, as shown in Table 2. A significant increase in ejection fraction was observed only in the LBBB cohort. Lack of reverse remodeling is consistent among the non-LBBB subgroups, with an LVESVi reduction of 6.6 mL/m² in patients with narrow QRS, 2.8 mL/m² for RBBB, and 8.6 mL/m² for IVCD. Model-based estimates for CRT effect are shown in Table 3 with corresponding 95% confidence intervals.

To evaluate the impact of QRS duration on remodeling parameters, patients were divided into quartiles based on the intrinsic QRS duration. The changes in LVESVi are shown in Table 4. The reduction of LVESVi increased progressively

---

**Table 1. Baseline Patient Characteristics**

<table>
<thead>
<tr>
<th></th>
<th>All Patients (n=610)</th>
<th>LBBB (n=369)</th>
<th>Non-LBBB (n=238)</th>
<th>P†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>62.5±11.0</td>
<td>62.3±11.3</td>
<td>63.0±10.3</td>
<td>0.42</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>479 (79)</td>
<td>266 (72)</td>
<td>210 (88)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>NYHA functional class II, n (%)</td>
<td>503 (82)</td>
<td>310 (84)</td>
<td>192 (81)</td>
<td>0.32</td>
</tr>
<tr>
<td>Ischemic, n (%)</td>
<td>333 (55)</td>
<td>160 (43)</td>
<td>173 (73)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Diabetic, n (%)</td>
<td>137 (22)</td>
<td>66 (18)</td>
<td>71 (30)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease, n (%)</td>
<td>60 (10)</td>
<td>34 (9)</td>
<td>26 (11)</td>
<td>0.49</td>
</tr>
<tr>
<td>ACE inhibitors or ARBs, n (%)</td>
<td>590 (97)</td>
<td>359 (97)</td>
<td>228 (96)</td>
<td>0.36</td>
</tr>
<tr>
<td>β-blockers, n (%)</td>
<td>580 (95)</td>
<td>351 (95)</td>
<td>226 (95)</td>
<td>1.00</td>
</tr>
<tr>
<td>Intrinsic QRS duration, ms</td>
<td>151±23</td>
<td>159±18</td>
<td>139±23</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>LV ejection fraction, %</td>
<td>62.7±7.0</td>
<td>26.6±7.0</td>
<td>26.7±7.2</td>
<td>0.88</td>
</tr>
<tr>
<td>LV end-diastolic dimension, cm</td>
<td>6.7±0.9</td>
<td>6.7±1.0</td>
<td>6.6±0.7</td>
<td>0.19</td>
</tr>
<tr>
<td>Interventricular mechanical delay, ms</td>
<td>33.6±39.0</td>
<td>47.6±33.7</td>
<td>11.8±36.6</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Minnesota Living With HF Score</td>
<td>27.6±20.6</td>
<td>26.2±19.1</td>
<td>29.7±22.7</td>
<td>0.055</td>
</tr>
<tr>
<td>6-min hall walk, m</td>
<td>395±127</td>
<td>408±122</td>
<td>374±132</td>
<td>0.001</td>
</tr>
<tr>
<td>CRT-D implanted, n (%)</td>
<td>508 (83)</td>
<td>292 (79)</td>
<td>213 (89)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

LBBB indicates left bundle-branch block; NYHA, New York Heart Association; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; LV, left ventricular; HF, heart failure, and CRT-D, cardiac resynchronization therapy with implantable cardioverter-defibrillator capabilities.

*For 3 patients, QRS morphology could not be classified.

†P values are for LBBB vs non-LBBB patients.

---

**Table 2. Effect of QRS Morphology on Changes in Echocardiographic Parameters at 12 Months**

<table>
<thead>
<tr>
<th></th>
<th>CRT OFF (n=39)</th>
<th>CRT ON (n=211)</th>
<th>P</th>
<th>CRT OFF (n=66)</th>
<th>CRT ON (n=131)</th>
<th>P</th>
<th>P for Interaction*</th>
</tr>
</thead>
<tbody>
<tr>
<td>LVESVi, mL/m²</td>
<td>−1.7±25.8</td>
<td>−25.3±28.5</td>
<td>&lt;0.0001</td>
<td>−1.5±19.7</td>
<td>−6.7±25.8</td>
<td>0.18</td>
<td>0.0003</td>
</tr>
<tr>
<td>LVEDVi, mL/m²</td>
<td>−1.8±30.0</td>
<td>−25.7±31.5</td>
<td>&lt;0.0001</td>
<td>−1.2±24.7</td>
<td>−8.5±30.5</td>
<td>0.11</td>
<td>0.0043</td>
</tr>
<tr>
<td>LVEF, %</td>
<td>0.8±6.9</td>
<td>6.9±9.7</td>
<td>&lt;0.0001</td>
<td>0.7±6.3</td>
<td>0.9±7.2</td>
<td>0.88</td>
<td>0.0002</td>
</tr>
</tbody>
</table>

LBBB indicates left bundle-branch block; CRT OFF, group with no cardiac resynchronization therapy; CRT ON, group with cardiac resynchronization therapy; LVESVi, left ventricular end-systolic volume index; and LVEF, left ventricular ejection fraction.

*Assesses the difference of CRT effect between LBBB and non-LBBB.
with QRS prolongation in the presence of CRT ($P < 0.0001$), with little change observed in the control population ($P = 0.87$; $P$ for interaction $< 0.0001$). Figure 1 illustrates the continuous relationship between QRS duration and change in LVESVi using spline smoothing. The relationship in the CRT ON group is fairly linear and intersects the CRT OFF group and a 0 change at a QRS duration of $\approx 120$ milliseconds.

When subgrouped by QRS morphology, the relationship between QRS duration and LVESVi noted above was due primarily to the LBBB cohort. Specifically, there was an estimated incremental decrease in LVESVi of $5.7 \text{ mL/m}^2$ for each 10-millisecond increase in the QRS duration by linear regression analysis among LBBB subjects ($P < 0.0001$; Figure 2A). No significant relationship between QRS duration and LVESVi was observed in the non-LBBB cohort (0.13 \text{ mL/m}^2; $P = 0.20$; Figure 2B). A similar interaction between QRS duration and morphologic variables was observed for LV end-diastolic volume index. Specifically, an estimated incremental decrease in LV end-diastolic volume index of $6.1 \text{ mL/m}^2$ for each 10-millisecond increase in QRS duration was noted for LBBB subjects ($P < 0.0001$), but no relationship between QRS duration and these volumetric changes was observed for non-LBBB subjects (0.39 \text{ mL/m}^2; $P = 0.81$).

**Clinical Response**

The primary end point for REVERSE was the CCS.$^9,17$ The results grouped by randomization and QRS morphology are summarized in Table 5. In the control arm (CRT OFF), the distribution of CCS was similar between the LBBB and non-LBBB groups ($P = 0.12$). CRT had no significant effect for the non-LBBB group (for CRT ON relative to CRT OFF: odds ratio, 0.724; $P = 0.21$) but markedly improved the CCS for the LBBB group (odds ratio, 0.530; $P = 0.0034$). However, the odds ratios for non-LBBB and LBBB were not significantly different ($P$ for interaction $= 0.35$). Of note, the response in the non-LBBB group was not homogeneous, with improved CCS for RBBB patients (odds ratio, 0.272; $P = 0.014$) but not for IVCD or narrow QRS. Odds ratio estimates for all groups are provided in Table 3.

In addition to the CCS, we evaluated the commonly used composite end point of time to first HF hospitalization or all-cause death. In the LBBB group, the curves diverged early and more end point events were observed in the CRT OFF cohort (hazard ratio, 0.48; $P = 0.028$; Figure 3A). Event rates were somewhat higher in the non-LBBB group and the curves also seemed to diverge, but this difference did not reach statistical significance (hazard ratio, 0.53; $P = 0.081$; Figure 3B). The hazard ratios for LBBB and non-LBBB are not significantly different ($P$ for interaction $= 0.86$). A significant reduction of events was observed in RBBB patients (hazard ratio, 0.683; $P = 0.0032$) but not in IVCD (hazard ratio, 0.60; $P = 0.31$) or narrow QRS (hazard ratio, 2.21; $P = 0.46$; see also Table 3).

**Table 3. Cardiac Resynchronization Therapy Effect Estimates by QRS Morphology**

<table>
<thead>
<tr>
<th>QRS Morphology</th>
<th>LVESVi change, mL/m²</th>
<th>LVEDVi change, mL/m²</th>
<th>LVEF change, %</th>
<th>CCS, odds ratio</th>
<th>Composite end point, HR</th>
</tr>
</thead>
<tbody>
<tr>
<td>LBBB (n=369)</td>
<td>−23.7 (−29.9 to −17.4)</td>
<td>−23.9 (−31.1 to −16.8)</td>
<td>0.13 (−0.2 to 0.47)</td>
<td>0.53 (0.35 to 0.81)</td>
<td>0.48 (0.24 to 0.94)</td>
</tr>
<tr>
<td>RBBB (n=55)</td>
<td>−3.5 (−19.1 to 12.0)</td>
<td>−4.5 (−22.3 to 13.3)</td>
<td>−0.2 (−5.0 to 4.7)</td>
<td>0.27 (0.10 to 0.77)</td>
<td>0.083 (0.01 to 0.69)</td>
</tr>
<tr>
<td>IVCD (n=126)</td>
<td>−7.8 (−18.3 to 2.6)</td>
<td>−10.5 (−22.5 to 1.5)</td>
<td>0.8 (−2.5 to 4.0)</td>
<td>0.79 (0.40 to 1.57)</td>
<td>0.60 (0.22 to 1.65)</td>
</tr>
<tr>
<td>Narrow QRS (n=57)</td>
<td>0.5 (−16.8 to 17.7)</td>
<td>−0.3 (−20.1 to 19.5)</td>
<td>0.0 (−5.9 to 4.8)</td>
<td>1.42 (0.46 to 4.34)</td>
<td>2.21 (0.27 to 18.0)</td>
</tr>
<tr>
<td>All (n=238)</td>
<td>−5.2 (−13.0 to 2.5)</td>
<td>−7.3 (−16.2 to 1.6)</td>
<td>0.2 (−2.2 to 2.6)</td>
<td>0.72 (0.44 to 1.20)</td>
<td>0.55 (0.26 to 1.09)</td>
</tr>
</tbody>
</table>

LBBB indicates left bundle-branch block; RBBB, right bundle-branch block; IVCD, intraventricular conduction delay; LVESVi, left ventricular end-systolic volume index; LVEDVi, left ventricular end-diastolic volume index; LVEF, left ventricular ejection fraction; CCS, clinical composite score; and HR, hazard ratio. Values in parentheses are 95% confidence intervals.

**Table 4. Effect of Intrinsic QRS Duration on Left Ventricular End-Systolic Volume Index Change at 12 Months**

<table>
<thead>
<tr>
<th>QRS Duration, ms</th>
<th>LVESVi change (ml/m²)</th>
<th>LVEDVi change (ml/m²)</th>
<th>LVEF change (%)</th>
<th>CCS, odds ratio</th>
<th>Composite end point, HR</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;134</td>
<td>−1.4±17.5 (38)</td>
<td>−5.2±20.5 (81)</td>
<td>0.87 (0.53)</td>
<td>0.35. (0.21)</td>
<td>0.48 (0.24)</td>
</tr>
<tr>
<td>134−152</td>
<td>3.5±20.7 (38)</td>
<td>−12.3±26.1 (88)</td>
<td>0.86 (0.46)</td>
<td>0.72 (0.44)</td>
<td>0.55 (0.26)</td>
</tr>
<tr>
<td>152−167</td>
<td>−7.7±21.9 (41)</td>
<td>−23.0±32.2 (82)</td>
<td>0.12 (0.60)</td>
<td>0.53 (0.21)</td>
<td>0.53 (0.26)</td>
</tr>
<tr>
<td>168−218</td>
<td>2.9±27.1 (44)</td>
<td>−33.3±29.2 (77)</td>
<td>0.53 (0.21)</td>
<td>0.72 (0.44)</td>
<td>0.53 (0.26)</td>
</tr>
<tr>
<td>All*</td>
<td>−0.7±22.5 (161)</td>
<td>−18.1±29.1 (328)</td>
<td>0.53 (0.21)</td>
<td>0.72 (0.44)</td>
<td>0.53 (0.26)</td>
</tr>
</tbody>
</table>

CRT OFF, group with no cardiac resynchronization therapy; CRT ON, group with cardiac resynchronization therapy.

*Baseline QRS and paired echocardiographic data are available for 489 patients.

![Figure 1](http://circ.ahajournals.org/content/110/5/e11002/F1.large.jpg)  
**Figure 1.** The absolute change in left ventricular end-systolic volume index (LVESVi) at 12 months. Each point represents data from 1 patient. The open symbols are for cardiac resynchronization therapy on (CRT ON) patients; closed symbols, control (CRT OFF) patients. The black line is the expected LVESVi change using spline smoothing for the CRT ON group; the gray line, the change for the CRT OFF group.
The effect of QRS duration on CCS was also evaluated. In the control arm (CRT OFF), there was no relationship between CCS and QRS duration (odds ratio, 1.016 for each 10-millisecond increase in QRS duration; \(P_{H11005} = 0.79\)). However, in the CRT arm, the association between CCS and QRS duration was highly significant (odds ratio, 0.831 for each 10-millisecond increase in QRS duration; \(P_{H11021} = 0.0001\)), with improved response at longer QRS durations. This relationship is further illustrated in Figure 4. Spline smoothing is used to plot the percentage of patients improved (ie, responders) in relation to QRS duration for the 2 randomized groups. There is little change in response for the CRT OFF group, whereas the proportion of responders increases as baseline QRS duration is prolonged in the CRT ON group. The curves cross at a QRS duration of \(\approx 115\) milliseconds, suggesting a lack of benefit of CRT in patients with narrow QRS.

The observed relations between outcome parameters and LBBB were also present in multivariable models that in-
cohort, and the magnitude of this response was strongly dependent on baseline QRS duration. Similarly, improvement in the CCS with CRT was larger in the LBBB cohort, and again it was related strongly to baseline QRS duration. Finally, the change in QRS duration with pacing was not an independent predictor of outcomes.

The results of the present study are consistent with several previous studies of QRS morphology on CRT in both the advanced and mild HF populations. Specifically, subgroup analyses of multiple trials of New York Heart Association class III/IV subjects showed minimal or no benefit in the presence of RBBB. The results for REVERSE were mixed with regard to response in RBBB subjects. The echocardiographic measures of reverse remodeling were attenuated and nonsignificant in this subgroup, although there was an improvement in clinical outcomes. More recently, the Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy (MADIT-CRT) evaluated the impact of QRS morphology on clinical response and noted benefit only in the LBBB subgroup, not in the composite of non-LBBB subjects.

The impact of QRS duration on outcomes has also been evaluated previously in CRT trials. Most commonly, QRS duration is dichotomized at 150 milliseconds for these analyses, with a smaller or no response observed among subjects with QRS duration <150 milliseconds. However, transforming a continuous measure such as QRS duration into a dichotomous one may not be optimal for analysis. Accordingly, we subdivided the cohort into quartiles based on unpaced QRS duration and analyzed outcomes with regression models that include QRS duration as a continuous parameter.

We observed that the relationship between QRS duration and response to CRT is best treated as a continuous variable, with larger response rates as QRS is prolonged. Moreover, the curve for change in LVESVi with CRT intercepts 0 at a QRS duration of ≈120 milliseconds, and the curves for active CRT and control for the CCS cross at ≈115 milliseconds. These similar observations are intriguing and indicate a lack of benefit among patients with narrow QRS, as shown in the subgroup analyses of that cohort. This is consistent with other multicenter studies of CRT specifically addressing this issue.

Although the change in QRS duration with biventricular pacing was associated with clinical outcomes, this effect was no longer significant in a multivariate model that corrected for baseline QRS duration. These 2 parameters were correlated. Thus, QRS duration tends to shorten more with longer baseline QRS durations and may even be prolonged with shorter baseline QRS durations. Accordingly, the change in QRS duration with pacing reflects primarily the intrinsic QRS duration. Although the total paced QRS duration was not an independent predictor of response, we did not evaluate whether other properties of the paced complex predicted response, as reported recently.

There are several clinical implications of these data. First, CRT in mild HF patients may need to be restricted to those with LBBB. Second, we found a progressive incremental

Figure 4. Effect of unpaced QRS duration on the proportion of patients with an improved clinical composite score. The curves use spline smoothing and are for the cardiac resynchronization therapy on (CRT ON) and control (CRT OFF) groups.

Paced QRS Duration
The immediate change in QRS duration with pacing has been reported to predict outcomes with CRT. To evaluate this possibility in REVERSE, we analyzed the acute QRS change in the CRT ON group. Acute QRS change was −6±26 milliseconds (LBBB, −13±24 milliseconds; non-LBBB, 3±26 milliseconds). For the primary end point, the association between CCS and acute QRS change is highly significant (odds ratio, 0.877 for each 10-millisecond additional acute decrease in QRS duration; P=0.0011). To explore these observations further, the relationship between unpaced baseline QRS duration and acute QRS change was analyzed, showing a moderate correlation (r=0.46, P<0.0001), and normalized QRS change was calculated. In a multivariable model for CCS with baseline QRS duration and normalized acute QRS change as covariates, only baseline QRS was significant (P<0.0001 in CRT ON arm versus P=0.20 for normalized acute QRS change). Similar results were observed with other end points. Specifically, the association between LVESVi change and acute QRS change was highly significant (P<0.0001). However, in the multivariate model, only baseline QRS was significant (P<0.0001 versus P=0.14 for normalized acute QRS change). Finally, in the CRT ON arm, the association between the incidence of death or HF hospitalization and acute QRS change was highly significant (P=0.0054), but only baseline QRS was significant (P=0.0002 versus P=0.39 for normalized acute QRS change) in the multivariate model.

Discussion
The primary results of this analysis suggest that the benefit of CRT in mild HF is strongly dependent on QRS morphology and duration. Specifically, echocardiographic changes in volumes and ejection fraction were noted only in the LBBB
response to CRT by increasing QRS duration but with no clear cutoff value for reverse remodeling or clinical benefit of CRT other than the conventional cutoff of 120 milliseconds. Thus, responses increase with increasing QRS prolongation but, importantly, with no response for QRS durations <115 to 120 milliseconds. Accordingly, CRT should be avoided in patients with narrow QRS, and the risks and benefits should be weighed carefully among subjects with only modest QRS prolongation or with non-LBBB morphology. Third, the change in QRS duration with pacing did not independently predict outcomes but rather was a reflection of intrinsic QRS duration.

This study should be interpreted in the face of several methodological limitations. First, randomization was not stratified on the basis of QRS morphology or duration, and many of these analyses were performed post hoc. Second, the study was not powered to detect any clinically relevant difference between QRS morphologies. Third, paired echocardiographic data were incomplete. However, this did not affect the outcomes. The CCS is improved in 260 of 509 patients with complete echocardiographic data (51%) and in 44 of 89 patients without complete echocardiographic data who survived through 12 months (49%; P = 0.68). Moreover, there is no observed difference in baseline LVEF between patients with (99 ± 38 mL/m²) and without (103 ± 37 mL/m²) complete echocardiographic data (P = 0.51). Finally, this study evaluated only subjects with mild HF, so the results may not necessarily apply to patients with more severe HF.

Conclusions

In a large cohort of patients with QRS prolongation, LV dilatation, but mild HF, CRT resulted in improved clinical response, fewer HF hospitalizations, and greater reverse remodeling. However, QRS morphology and duration had important impacts on these end points. Specifically, little remodeling or clinical benefit was observed in the absence of LBBB. Additionally, both remodeling and clinical responses increased progressively with increasing baseline QRS duration compared with little or no response in unpaced control subjects or QRS durations <120 milliseconds.

Sources of Funding

This work was supported by Medtronic Bakken Research Center BV, Maastricht, Netherlands and Medtronic, Inc, Minneapolis, MN.

Disclosures

Drs Gold, Linde, St. John Sutton, and Daubert served as consultants to and received research grants from Medtronic. Drs Gold and Linde served as consultants to and receive research grants from St. Jude Medical. Dr Linde reports honoraria payments from Biotronik and St. Jude. Dr. Abraham reports consulting fees from St. Jude Medical, Medtronic, and St. Jude. Dr. Abraham reports consulting fees from Biotronik, Sorin, and Boston Scientific. Dr Gerritse is an employee of Medtronic. Dr Thébault reports research grants from Medtronic. Dr Ghiro reports no conflicts.

References

Cardiac resynchronization therapy (CRT) decreases mortality, improves functional status, and induces reverse left ventricular remodeling in selected populations with both mild and advanced heart failure. Despite these benefits of CRT, nearly one third of subjects are typically classified as nonresponders. Characteristics of the surface ECG have been shown to be important predictors of response in several previous studies. In the present analysis of the Resynchronization Reverses Remodeling in Systolic Left Ventricle Dysfunction (REVERSE) trial, the impact of baseline QRS duration and morphology and the change in QRS duration with pacing on outcomes in mild heart failure with CRT were described. Patients with left bundle-branch block experienced large reductions in left ventricular volumes, whereas patients with non−left bundle-branch block had much smaller decreases. Baseline QRS duration was also a strong predictor of remodeling, with monotonic increases as QRS duration prolonged and no obvious threshold above 120 milliseconds. Similarly, clinical outcomes improved with CRT for left bundle-branch block subjects but not for non−left bundle-branch block subjects, and clinical outcomes increased as QRS duration prolonged. The change in QRS duration with CRT pacing was not an independent predictor of any outcomes after correction for baseline variables. These data indicate that left bundle-branch block and QRS prolongation are markers of reverse remodeling and clinical benefit with CRT in mild heart failure. However, the change in QRS duration with biventricular pacing is not a useful predictor of response independently of the baseline ECG characteristics. Finally, despite the relationship between QRS duration and outcomes, these results do not support the use of any arbitrary QRS duration cutoff >120 to 130 milliseconds for selecting CRT candidates.
Effect of QRS Duration and Morphology on Cardiac Resynchronization Therapy Outcomes in Mild Heart Failure: Results From the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) Study
Michael R. Gold, Christophe Thébault, Cecilia Linde, William T. Abraham, Bart Gerritse, Stefano Ghio, Martin St. John Sutton and Jean-Claude Daubert

_Circulation_. 2012;126:822-829; originally published online July 10, 2012; doi: 10.1161/CIRCULATIONAHA.112.097709

_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2012 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/126/7/822

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org/subscriptions/